Receptor Grade IGF-1 LR3 (100mcg)


Size: 100mcg
Contents: Receptor Grade IGF-1 LR3 (100mcg)
Form: Lyophilized powder
Purity: >99%
SKU: P-IGF1LR3-100

FREE Shipping on $200+ orders

FREE Bacteriostatic Water (30ml) on $200+ orders

Discount per Quantity

5 - 85%$25.65
9 +10%$24.30
SKU: P-IGF1LR3-100 Category:


Receptor Grade IGF-1 LR3 Peptide

Insulin-like Growth factor-1, or IGF-1, is a naturally produced protein composed of 70 amino acids. Structurally similar to insulin, this IGF-1 LR3 has the potential primarily in regulating cell tissue and body growth and development. There are two synthetic variations of IGF-1; firstly, the synthetic IGF-1, which was developed with the intention of identically  mimicking to the natural protein and possibly stimulating similar effects as IGF-1; and second, is Receptor Grade IGF-1 LR3, which is also synthetic in nature, but may exhibit higher efficacy than the natural protein.

Receptor Grade IGF-1 LR3 is a synthetic variant of the naturally occurring IGF-1, which contains an extended N-terminal structure and arginine acid at residue 3. Hence, it is named IGF-1 Long R3 (2). Owing to the altered structure, IGF-1 LR3 has been suggested to bind poorly with type 1 IGF-1 receptors, potentially increasing blood plasma concentration of the IGF binding proteins.

Receptor Grade IGF-1 LR3 Chemical Makeup(2,3)

Molecular Formula: C400H625N111O115S9
Molecular Weight: 9117.5 g/mol
Other known titles: Long-(arg3) insulin-like growth factor-I, Insulin-like growth factor long chain R3

Research and Clinical Studies

Receptor Grade IGF-1 LR3 and Insulin-Like Growth Factor Deficiencies

A study(4) was conducted in 2005 to study the potential of the peptide in subjects with IGF-2 deficiency and growth ailments. There were 45 subjects with naturally short stature enrolled in this clinical trial, where the peptide was presented once daily. The heights of the subjects were measured prior the study, and after completion of the trial, they were measured again as part of the analysis. Based on the reports, it was observed that the height had increased in all subjects presented with the peptide by an average of 7 cm. This study suggests that IGF-1 analogs, including Receptor Grade IGF-1 LR3 peptide, may have some potential in mitigating growth deficiency.

Receptor Grade IGF-1 LR3 and Lipid Metabolism

Research(5) has suggested that IGF proteins typically bind to IGF-1 receptors and may stimulate glucose uptake. This binding may trigger glucose metabolism via a signaling mechanism. Peptides like Receptor Grade IGF-1 LR3, when studied, appeared to induce similar results, suggesting that the glucose uptake may not be triggered due to binding with IGF-1 receptors. When glucose uptake is triggered, it possibly leads to an overall reduction in the blood sugar levels in the body. Due to less sugar, the adipose (fatty) tissue and liver cells get activated to conduct lysis of the stored body glycogen and fats. Therefore, Receptor Grade IGF-1 LR3 may have the potential to enhance lipid metabolism. Assefa B Mahmoud et al. stated, "Multiple [...] studies reported the role of IGF-1 in enhancing insulin sensitivity and glucose metabolism. A low-serum level of IGF-1 has been associated with insulin resistance, and treatment with recombinant IGF-1 has been shown to improve insulin sensitivity and glucose metabolism.”

Receptor Grade IGF-1 LR3 and Lifespan

Research(6) on experimental rodents observes that when presented with the peptide, several common aging ailments such as muscle tears and dementia, appear to be prevented for an extended period. While more detailed studies and clinical trials are pending, the above preliminary study suggests that the peptide may indirectly help to increase life span. As per William E. Sonntag et al., “Based on this review, we conclude that the perceived contradictory roles of growth hormone and insulin-like growth factor-1 in the genesis of the aging phenotype should not be interpreted as a controversy on whether growth hormone or insulin-like growth factor-1 increases or decreases life span but rather as an opportunity to explore the complex roles of these hormones during specific stages of the life span.”

Receptor Grade IGF-1 LR3 and Muscle

A study(7) was conducted on female mice to identify the Receptor Grade IGF-1 LR3 peptide’s potential for decreasing myostatin's action. Myostatin prevents cellular differentiation; preventing the effects of this protein helps increase lean muscle and reduce fatty mass. The study's results suggested that the various IGF-1 analogs, including Receptor Grade IGF-1 LR3, appear to potentially reverse adverse myostatin and prevent apoptosis.

Receptor Grade IGF-1 LR3 and Extended Action

For this study(8), an experimental mouse model was created where the Receptor Grade IGF-1 LR3 peptide replaced the endogenous IGF-1. Throughout the study, it was observed that when the peptide was presented, it appeared to quickly clear from the serum and evenly distributed into tissue. Post-completion of the study, it was suggested that these experimental mice showed increased growth and strength, with an improved robust skeletal system, compared to the controls. Also, since the Receptor Grade IGF-1 LR3 peptide possibly binds poorly with the IGF-1 receptors, their plasma concentration may remain higher for extended periods.

Receptor Grade IGF-1 LR3 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.


  1. Tomas, F. M., Knowles, S. E., Owens, P. C., Chandler, C. S., Francis, G. L., Read, L. C., & Ballard, F. J. (1992). Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. The Biochemical journal, 282 ( Pt 1)(Pt 1), 91–97.
  2. Human Insulin-like growth factor. Protein Data Bank in Europe,
  3. National Center for Biotechnology Information (2023). PubChem Substance Record for SID 381123731, M9L22Y19H9, Source: ChemIDplus. Retrieved January 24, 2023 from
  4. Anderson, L. J., Tamayose, J. M., & Garcia, J. M. (2018). Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. Molecular and cellular endocrinology, 464, 65–74.
  5. Assefa, B., Mahmoud, A. M., Pfeiffer, A., Birkenfeld, A. L., Spranger, J., & Arafat, A. M. (2017). Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. Oxidative medicine and cellular longevity, 2017
  6. William E. Sonntag, Anna Csiszar, Raphael de Cabo, Luigi Ferrucci, Zoltan Ungvari, Diverse Roles of Growth Hormone and Insulin-Like Growth Factor-1 in Mammalian Aging: Progress and Controversies, The Journals of Gerontology: Series A, Volume 67A, Issue 6, June 2012, Pages 587–598,
  7. Naisi Li, Qiyuan Yang, Ryan G. Walker, Thomas B. Thompson, Min Du, Buel D. Rodgers, Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis, Endocrinology, Volume 157, Issue 1, 1 January 2016, Pages 282–291.
  8. Yakar, S et al., 40 YEARS OF IGF1: Insulin-like growth factors: actions on the skeleton (Jul 2018). Journal of Molecular Endocrinology, vol. 61 Issue 1.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

    Your Cart
    Your cart is empty